I
schemic stroke is caused by a thrombus that blocks an intracranial artery. Brain tissue beyond the blocked artery survives for a variable period of time because of blood and nutrients (perfusion) received through tiny vessels called collaterals. 1 An ideal patient for revascularization therapy should therefore have a target thrombus and brain that is alive but at risk of dying within the next few hours because of tenuous perfusion through collaterals. Imaging helps identify target intracranial thrombi and measure extent of salvageable brain. Imaging the brain and the vasculature that supplies it is therefore a vital first step in treating patients with acute ischemic stroke.
Until recently, intravenous tissue-type plasminogen activator (tPA) has been the only reperfusion therapy proven to reduce disability after acute ischemic stroke. 2 A computed tomographic (CT) scan of the brain is needed in such patients to rule out hemorrhage before intravenous tPA can be given. Unfortunately, although intravenous tPA is effective at recanalizing smaller distal thrombi, it succeeds in dissolving larger more proximal thrombi only 15% to 25% of the time. [3] [4] [5] Endovascular therapy uses mechanical devices delivered via catheter angiography to recanalize intracranial arteries blocked by thrombi. Recent clinical trials Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN), Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times (ESCAPE), Extending the Time for Thrombolysis in Emergency Neurological Deficits-IntraArterial (EXTEND-IA), and Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment (SWIFT PRIME) have shown efficacy of adding endovascular therapy versus standard care in treating patients with acute anterior circulation ischemic stroke. [6] [7] [8] [9] A major difference between these positive endovascular trials and reperfusion trials in the past was in the use of CT angiography (CTA) to select patients with proximal intracranial thrombi [10] [11] [12] (Table) . MR CLEAN did not specify any further imaging eligibility criteria, but the ESCAPE, EXTEND-IA, and SWIFT PRIME clinical trials also selected patients with a
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small ischemic core at baseline and either adequate collaterals (using CTA in ESCAPE) or salvageable brain (using CT perfusion [CTP] in EXTEND-IA and the majority of patients in SWIFT PRIME) [7] [8] [9] (Table) . These trials focused on efficiently integrating advanced CT imaging within the stroke workflow by developing and using imaging techniques that are quick, reliable, and available at all hours of day.
The dramatic results of these trials raise the following questions: What is the evidence that supports the use of various imaging tools in selecting patients for endovascular therapy? What imaging tools should be used in the general population and within different health systems? and What are the challenges in implementing the use of these imaging tools?
In the context of the recent clinical trials showing benefit of endovascular therapy in patients with acute ischemic stroke, this review summarizes current knowledge on the use of imaging in patient selection while trying to answer the above questions.
What Is the Evidence That Supports the Use of Imaging Tools in Selecting Patients for Endovascular Therapy?
Noncontrast CT Noncontrast CT (NCCT) is the most widely used first-line imaging tool in patients with acute stroke. NCCT is quick to acquire, widely available, and discriminates reliably between ischemia and hemorrhage. 13 It is therefore a useful screening tool in the acute stroke workflow. NCCT is also used to measure the extent of early ischemic changes (EIC) within ischemic brain. The Alberta Stroke Program Early CT Score (ASPECTS) is a simple and systematic approach to assessing EIC (subtle parenchymal hypo-attenuation) within the middle cerebral artery territory on NCCT 14 ( Figure 1) . Data from the Prolyse in Acute Cerebral Thromboembolism II (PROACT-2) clinical trial and the Penumbra Pivotal Studies suggested that patients with proximal middle cerebral artery occlusions and poor baseline ASPECTS may not benefit from recanalization therapy. [15] [16] [17] Although the MR CLEAN trial protocol did not specify limits on the extent of EIC, the point estimate for treatment effect in the prespecified subgroup with ASPECTS<5 was close to unity (adjusted common odds ratio, 1.09; 95% confidence interval, 0.14-8.46). 6 Moreover, the trial only had 28 in 496 (5.6%) with ASPECTS<5 at baseline, raising the possibility that investigators may have used their discretion to exclude patients with extensive EIC on NCCT from the trial. 6 EIC assessment on NCCT, however, has modest inter-rater reliability, even among experts. 18 Reliability is less in the ultraearly presenters (within 90 minutes from stroke symptom onset). 19 It is important to note that inter-rater reliability is a function of scan quality and also depends on whether ASPECTS is analyzed as individual point scores or at a decision-making level (eg, dichotomized as <6 versus ≥6), which is less variable. It is possible that with increasing efforts toward standardization of NCCT image quality, better training, and moving to a decision-making-based imaging paradigm, inter-rater reliability of NCCT may improve. The ESCAPE trial provided an innovative solution to this issue by using collateral assessment on CTA along with ASPECTS on NCCT.
7

CT Angiography
Identifying the Presence of Target Thrombus
Angiographic studies show that a large proportion of patients with acute ischemic stroke (19%-39%) have no identifiable intracranial occlusion. 20 The presence of a proximal intracranial occlusion identifies patients who could be severely disabled on long-term follow-up. CTA is a rapid, easily available imaging tool for detecting intracranial occlusions in patients with acute ischemic stroke, thereby guiding therapy. 21 All 4 recently positive endovascular trials used CTA as an imaging selection tool to identify patients with proximal anterior circulation occlusions. [6] [7] [8] [9] Even in the Interventional Management of Stroke (IMS) III trial, which was neutral overall, there was a significant benefit of endovascular therapy versus intravenous tPA alone in patients selected using CTA. 22 Moreover, 8% of patients undergoing CTA in this trial did not have a target occlusion, a necessary precondition for initiating endovascular therapy.
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Arch, Extracranial, and Intracranial Vascular Anatomy CTA may also be helpful to neurointerventionists when planning an endovascular procedure. 21 Neurointerventionists need previous information on the anatomy of the arch of aorta, and tortuosity of the proximal extracranial neck vessels helps decide on the appropriate catheters and techniques that will help achieve quick and safe recanalization. 23 Knowledge of the status of the ipsilateral carotid bifurcation helps plan for appropriate guide catheter. Information on Willisian collaterals and site and size of thrombus within the arterial tree determines the choice of endovascular technique. Device profiles of present generation devices, such as stentrievers, are tailored to the target artery with each device available in different sizes. Increasingly, modern neurointerventional practice is based on achieving recanalization using multiple devices and 
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techniques tailored to the needs of a specific situation. 23 CTA provides high-resolution images of the arch of aorta, neck vessels, and intracranial circulation, including thrombus location and size, and helps tremendously in the acute decision-making process by reducing time to optimal device deployment and enhancing safety of the procedure. 21 In analysis of data from the IMS III trial, patients who had baseline CTA had ≈20 minutes shorter emergency room arrival to reperfusion times compared with those who did not have CTA (P=0.008).
24
Assessment of Collateral Status Using CTA Ischemic brain depends on blood flow from collaterals to survive until the occluded artery is opened. This collateral circulation is highly variable and significantly influences the rate at which an infarct grows. 1 Patients with good collaterals generally have a lower risk of more extensive established infarction, however, patients with poor collaterals have minimal or no salvageable tissue at presentation. Effective collateral assessment could therefore decide who will benefit from early recanalization. Using CTA, collateral status in the ischemic hemisphere can be measured by comparing backfilling pial arteries beyond the blocked artery to similar arteries in the opposite unaffected hemisphere. 25, 26 Multiple previous studies including a post hoc analysis of the IMS III trial show that patients with adequate collaterals on CTA are likely to do better with endovascular therapy when compared with intravenous tPA while patients with poor collaterals are unlikely to show a differential effect of therapy and may even be harmed. [27] [28] [29] A major disadvantage of collateral assessment on conventional CTA is that it is a single snap shot in time of contrast filled blood vessels. It therefore risks misclassifying patients with adequate collaterals as poor if acquired early in the arterial phase. 30 Multiphase CTA (mCTA) is a technique that generates time-resolved cerebral angiograms of the brain vasculature from skull base to vertex 30 ( Figure 1) . A standard aortic arch-vertex CTA performed using a multi-detector CT scanner is the first phase. This acquisition is timed to be in the late arterial phase by triggering the scan based on bolus monitoring. The remaining 2 phases are from skull base to vertex in mid venous and late venous phase. The 2 additional phases of mCTA use no additional contrast; the total radiation dose is minimal. 1 The ESCAPE trial used collateral assessment (on mCTA in a majority) to select patients 7 (Table) . Significantly, collateral assessment was used to help improve the accuracy of ASPECTS interpretation on NCCT. The ESCAPE trial collateral assessment on CTA matched with the ASPECTS anatomic template on NCCT; minimal or no pial collaterals in >50% of the ischemic anterior circulation corresponded to an ASPECTS score of 5 or less in patients with internal carotid artery or middle cerebral artery M1 segment occlusion 7 ( Figure 1 ). This novel combined NCCT and collateral imaging criteria was associated with only 3.6% protocol violation based on central adjudication of baseline NCCT ASPECTS, a number that is low when considered in the context of the rapid enrollment (1.44 participants per site per month) in the trial. 7 With appropriate education and training in the use of mCTA along with a focus on speed, the major clinical benefit (absolute reduction in disability of 25%) in the ESCAPE trial may potentially be applicable to the broader population of ischemic stroke patients with proximal large vessel occlusion.
Perfusion Imaging
CTP was universally used to select patients for the EXTEND-IA trial 8 (Table; Figure 2 ). It was also performed in 81% of patients in SWIFT PRIME (84% of whom had a target mismatch profile; Table) . 9 Eligibility criteria required evidence of salvageable tissue and excluded patients with a large ischemic core: >70 mL in EXTEND-IA and >50 mL in SWIFT PRIME which had an additional exclusion if >100 mL severe hypoperfusion (T max >10 s). Part-way through SWIFT PRIME, the protocol was modified to make CTP optional because of a desire to maximize recruitment and workflow efficiency, and concern that some sites could not perform whole-brain CTP without the use of table movement (which was permitted in EXTEND-IA but not in SWIFT PRIME). There is evidence that CTP is more sensitive than NCCT for identifying ischemic core.
31,32 CTP also provides information about the area of tissue at risk. Although this can be estimated based on the site of vessel occlusion, considerable anatomic variability makes it difficult to assess extent of potentially salvageable tissue in patients with a moderately large ischemic core unless perfusion imaging is performed. Time to maximum (T max ) >6 s has been validated in multiple studies as a good approximation of tissue at risk. [33] [34] [35] [36] Patients with large ischemic core or regions of severe hypoperfusion on CTP 37 are also at increased risk of hemorrhagic transformation, and the imaging selection may have contributed to the relatively low rates of symptomatic intracerebral hemorrhage in the recent trials. [6] [7] [8] [9] Criticisms of CTP in the past have included limited brain coverage, potential variation in processing methodology and interpretation, and the time taken to acquire and process the imaging. 38 Newer CT scanners are capable of whole-brain CTP; limited brain coverage will rapidly cease to be an issue. The fully automated software used in EXTEND-IA and SWIFT PRIME allowed standardization of processing methodology, perfusion map appearance, and objective segmentation of lesion volumes across the range of hardware platforms in use across these multicenter trials. 39 Automation was also robust to common artifacts. 40 Delays to acquire and process CTP imaging are often cited but the acquisition itself takes ≈60 to 90 s, and when automated software is used, the subsequent reconstruction and processing time along with interpretation can occur in <5 minutes. 40 The removal of the need for trained personnel to produce perfusion maps facilitates rapid interpretation by the clinician, particularly after hours. Whether these efficiencies can be routinely implemented is yet to be seen. In addition, challenges related to motion correction, partial recanalization into already infarcted tissue at the time of imaging and refinement of core, and penumbral selection criteria will continue to evolve.
CTP has other potential advantages. It provides an objective quantitative assessment of irreversibly injured brain and tissue at risk, unlike the ASPECT score on NCCT. Dynamic angiography generated from raw CTP data can be used to grade collaterals with excellent temporal resolution if the clinician prefers that approach. 41, 42 Dynamic CTA can also differentiate complete occlusion because of thrombi from high-grade stenosis or nonocclusive thrombus; a finding that has implications in predicting the likelihood of early recanalization with intravenous tPA. 43 Indeed some of the commercially available, fully automated CTP software include dynamic angiography in the standard output. 44 Trials such as EXTEND-IA and SWIFT PRIME demonstrate the feasibility of modern CTP with standardized automated processing in the time-critical clinical environment 8, 9 ( Table) . Whether selection is based on mismatch criteria and an absolute volume of ischemic core, as used in these studies, or a more flexible approach that weighs core volume and location with other factors, such as time and premorbid health, remains to be determined. However, a wealth of information can be rapidly gained through perfusion imaging that has great potential to inform clinical decisions.
MR Imaging
Magnetic resonance imaging (MRI) as an imaging selection tool for use in patients with acute ischemic stroke has some practical drawbacks. Diffusion MRI provides the most accurate assessment of ischemic core, and short 6-minute stroke protocols have been described. 45 However, even with an abbreviated imaging protocol, the time taken to screen the patient for metallic implants and access the scanner (which is usually in constant use) needs to be considered. 46 In the EXTEND trial of tPA versus placebo 4.5-9 hours post stroke, MRI-selected patients had a median door to needle 78-min longer than CT-selected patients. 40, 47 It is more difficult to monitor unstable patients in MRI, and images tend to be more susceptible to patient motion. MRI availability after hours is often limited. Given the critical importance of time, access to MRI in many centers would need to be improved to achieve similar speed to CT-based imaging.
What Imaging Tools Should Be Used in the General Population and Within Different Health Systems?
There is a strong consensus in the stroke community that time is brain. Any imaging strategy that produces significant delays in the stroke workflow should therefore be avoided. In addition, on the basis of recent evidence, CT-based imaging will be the mainstay of acute stroke imaging. [6] [7] [8] [9] Patients will first undergo NCCT head to rule out hemorrhage. They will then have a CTA to document the presence or absence of target vessel occlusion and allow for planning of the possible endovascular treatment. The application of more advanced CT imaging paradigms, such as mCTA, to assess the status of collaterals or CTP with standardized automated ischemic core and penumbral volume measurement is supported by ESCAPE, EXTEND-IA, and SWIFT PRIME. However, the authors acknowledge that some patients excluded from these trials but included in MR CLEAN may still benefit, and this requires further study. The additional time delay to treatment decision with mCTA is short (15 s of additional imaging, no additional contrast, no post processing, and little vulnerability to motion). 30 The acquisition and processing time for CTP in experienced centers are ≈5 to 8 minutes; controlled studies from centers with high-level expertise in CTP suggest that no time penalty is incurred when CTP is used to guide intravenous thrombolytic therapy. 40, 48 We feel that both approaches are reasonable based on current evidence in anterior circulation strokes (with little data on their application in basilar occlusion). However, with both techniques, adequate technical and interpretation training and experience are essential.
Health systems are often structured in hub and spoke arrangements with networked community hospitals, primary stroke centers, and tertiary or comprehensive stroke centers, the latter providing the option of endovascular therapy. The evidence for endovascular therapies suggests that all facilities managing patients with acute stroke should develop capability to perform CTA to identify potential candidates for endovascular therapy. The complexity of the imaging that should be done at a primary stroke center before referral to a tertiary stroke center offering endovascular therapy is a topic of discussion. The recently positive trials point in the direction of the need to develop advanced CT imaging capability in primary stroke centers, allowing efficient triage of appropriate patients to achieve complete and safe reperfusion in as many
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June 2015 patients as early as possible. Geographical distances between first patient contact, primary, and tertiary stroke center, as well as health system resources, including response time and type of transport available along with prevalence of stroke and economics of acquiring equipment and hiring personnel, will play a major role in determining the most efficient spread of imaging tools within hospitals in each health system. It is highly likely that time from onset to imaging will decide the likelihood of favorable imaging (absence of large core) in patients with proximal vessel occlusion and in patients selected for endovascular therapy based on imaging criteria, time from imaging to reperfusion will decide likelihood of a good outcome.
47
What Are the Challenges in Implementing the Use of These Imaging Tools?
There is an immediate need for standardization of imaging quality and protocols. For any imaging to be effective, it has to be of sufficient quality to allow visualization of the relevant findings. Quality in CT (NCCT, CTA, or CTP) acquisition and interpretation can be affected by multiple factors. Broadly, these can be divided into: (1) imaging equipment, for example, age of scanner, vendor, and type of noise reduction algorithms; (2) scanner setup, for example, what keV and mAS have been used and whether the acquisition was spiral or sequential; (3) expertise of technologist, for example, bolus timing in CTA, placement of appropriate imaging slab in CTP, and repeating relevant slices if there is patient motion; (4) patient factors, for example, cardiac output, gauge of IV access, patient motion, etc; (5) image processing (mainly for CTP), for example, quality of motion correction algorithm, variability in processing algorithm, definition of irreversibly injured brain versus salvageable brain, etc; and (6) physician factors, for example, background training (neurosurgeon versus radiologist versus neurologist), comfort with imaging software, ability to recognize and fix artifacts, and ability to see the imaging data in the context of the overall picture including clinical information. Some of these factors are easy to fix, whereas others will require more effort. Variance at the level of data acquisition should be the easiest. One of the authors (M.G.) traveled to >30 stroke centers are part of ESCAPE and SWIFT PRIME and found significant variance in imaging acquisition between sites. The ESCAPE, EXTEND-IA, and SWIFT PRIME trials tackled this problem by conducting multiple quality assessments and training sessions throughout the running of the trials. [7] [8] [9] In our opinion, therefore, there is an urgent need for our field to achieve precise consensus recommendations about CT acquisition techniques and parameters. We strongly encourage industry to participate in this process.
Lack of standardization in CTP data processing has been an important barrier to more widespread implementation of CTP in acute stroke workflow. 49 A major reason for lack of standardization has been the requirement for manual input from technicians, clinicians, or both to generate perfusion maps. Manual input requires training, on-line time, and judgment. Another reason has been variability in perfusion image analysis software packages. The EXTEND-IA and SWIFT PRIME trials tackled this problem by using fully automated software that produced maps and also used validated thresholds to segment regions of brain likely to be irreversibly injured versus potentially salvageable. 8, 9 Major effort is required on educating the end-user on the use of imaging for clinical decision making in patients with acute stroke. This focus on education should not only be on accurate interpretation of imaging data but also on better understanding of the imaging equipment, processing software, potential imaging artifacts, and an ability to use whatever imaging available (if certain imaging modalities are not available because of extraneous factors, such as patient motion) to make quick and appropriate clinical decisions. The Web site http://www.aspectsinstroke.com serves this purpose for a NCCT+mCTA paradigm. An important element of education is minimizing treatment delay by having parallel systems in place leading to the goal of achieving quick reperfusion. Thus, intravenous tPA administration in the imaging suite just after NCCT while setting up the processes for acquiring CTA/CTP should be encouraged. 23 Similarly, patients should be physically moved toward the angiography suite for endovascular procedure, whilst CTA or CTP is being interpreted. 23 Of note, in complex cases or where there is diagnostic uncertainty, CTA/mCTA/CTP will add to the diagnostic confidence of the treating physician, thus reducing delays incurred because of therapeutic indecision.
Other common concerns with CT-based imaging are the radiation dose and contrast complications. Although there have been highly publicized errors in CT dosing, quality multimodal CT acquisitions can be obtained at acceptable doses. 30 Concern about contrast nephropathy associated with intravenous iodinated contrast is also overstated with several institutions reporting on safety of administering contrast without any renal screening procedures. Therapy of acute ischemic stroke is constantly evolving. Two of the imaging trials (ESCAPE and SWIFT PRIME) were able to accomplish dramatic improvements in workflow with median imaging to first recanalization time of <90 minutes 7, 9 ( Table) . With continued efforts in improving workflow and training along with availability of additional resources to hospitals given positive trial results, these times will further improve. 23 In addition, a concerted effort toward patient education and training of paramedics will likely ensure that more patients with stroke will arrive earlier to appropriate hospitals. Overall, this should result in further increase in the benefits seen with endovascular therapy within these trials.
One unanswered question is whether patients who arrive late or with unknown stroke onset time can be safely and effectively treated. The ESCAPE trial enrolled 49 patients presenting beyond 6 hours from stroke onset with the point estimate being in favor of endovascular therapy (modified Rankin Scale, 0-2 at 90 days; relative risk, 1.7; 95% confidence interval, 0.7-4.0). 7 The proportion of patients with salvageable brain declines over time, whereas the risk of reperfusion potentially increases with time. It is however reasonable to hypothesize that imaging will be able to identify patients who may still benefit with reperfusion at later time points. Imaging could also potentially be used to identify patients who could benefit from neuroprotection or from collateral augmentation. It is highly unlikely that patients with large baseline ischemic core would benefit from such therapy. Imaging at primary stroke centers could identify candidate patients with optimal signatures that may then be referred to tertiary care hospitals for endovascular therapy, whereas neuroprotectants or collateral augmentation strategies are administered.
Summary and Take Home Message
Each of the positive endovascular trials has taken a slightly different approach to patient selection based on brain imaging (Table) . The common theme in the more imaging selective trials has been to exclude patients with a large area of irreversibly injured ischemic core; it is noteworthy that even in least selective trial, MR CLEAN, the median ASPECTS score in both patient groups was 9. In this light, rapid CT-based selection embedded within streamlined clinical assessment protocols, where imaging is used to exclude patients with evidence of large ischemic core (low ASPECTS on NCCT, poor collaterals on mCTA, or evidence of a large ischemic core on CTP) is attractive. This is illustrated by the fact that the 3 trials using these imaging approaches all had to be stopped early on the basis of a much greater than expected treatment effect. [7] [8] [9] The eligibility criteria for entry into these trials, that is, a proximal occlusion and substantial amount of potentially salvageable ischemic tissue was purposely set to avoid the likelihood of futile reperfusion. Although less stringent entry criteria would likely reduce treatment effect size, we do not know whether clinically relevant improvement in patient outcomes could potentially be seen in patients with less favorable imaging parameters. As knowledge accumulates in imaging-based selection, it is likely that more sophisticated imaging selection algorithms will be developed that present clinicians with a range of probabilities of long-term outcome with or without treatment as a guide to making clinical decisions. Going into the future, we collectively will need to decide whether we favor a more selective strategy (acknowledging that patients who may benefit may not get the treatment) or a more inclusive strategy that takes many more patients for endovascular treatment (leading to greater numbers of futile recanalization).
It is clear that imaging shall play a key role in treatment decisions for acute stroke. However, the authors strongly think that any imaging has to be interpreted and synthesized with clinical information. Factors such as patient age, premorbid status, patient's wishes and expectations of good outcome, and time from onset remain important. At the highest level, it is important to remember that decision-making is dichotomous (treat the patient or not treat the patient) and that time is brain. As endovascular therapy is established in standard practice and further efficiencies develop, it is possible that the extent of imaging acquired will be adjusted based on the clinician's level of confidence in making a treatment decision in the individual patient. 
